Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
  • About
    • General information
    • Staff
    • Editorial board
    • Open access
    • Contact
  • CMAJ JOURNALS
    • CMAJ
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ Open
  • CMAJ JOURNALS
    • CMAJ
    • CJS
    • JAMC
    • JPN
CMAJ Open

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
  • About
    • General information
    • Staff
    • Editorial board
    • Open access
    • Contact
  • RSS feeds
Research

Deaths from exposure to paramethoxymethamphetamine in Alberta and British Columbia, Canada: a case series

Jennifer J.E. Nicol, Mark C. Yarema, Graham R. Jones, Walter Martz, Roy A. Purssell, Judy C. MacDonald, Ian Wishart, Monica Durigon, Despina Tzemis and Jane A. Buxton
March 04, 2015 3 (1) E83-E90; DOI: https://doi.org/10.9778/cmajo.20140070
Jennifer J.E. Nicol
1Department of Emergency Medicine, University of Calgary, Calgary, Alta.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark C. Yarema
1Department of Emergency Medicine, University of Calgary, Calgary, Alta.
2Poison and Drug Information Service, Alberta Health Services, Calgary, Alta.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham R. Jones
3Office of the Chief Medical Examiner, Edmonton, Alta.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walter Martz
6Provincial Toxicology Centre, Vancouver, BC
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roy A. Purssell
7British Columbia Drug and Poison Information Centre, Vancouver, BC
8Department of Emergency Medicine, University of British Columbia, Vancouver, BC
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judy C. MacDonald
9Population, Public and Aboriginal Health, Alberta Health Services — Calgary Zone, Calgary, Alta.
10Department of Community Health Sciences, University of Calgary, Calgary, Alta.
MDMCM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Wishart
1Department of Emergency Medicine, University of Calgary, Calgary, Alta.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monica Durigon
11Environmental Health Services, British Columbia Centre for Disease Control, Vancouver, BC
12Canadian Field Epidemiology Program, Public Health Agency of Canada, Ottawa, Ont.
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Despina Tzemis
5British Columbia Centre for Disease Control, Vancouver, BC
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane A. Buxton
4School of Population and Public Health, University of British Columbia, Vancouver, BC
5British Columbia Centre for Disease Control, Vancouver, BC
MBBSMHSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • Figure 1:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1:

    The chemical structures of paramethoxymethamphetamine (PMMA) and methylenedioxymethamphetamine (MDMA or “ecstasy”).

  • Figure 2:
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2:

    Antemortem end-organ dysfunction based on clinical findings and investigations of 13 of the 17 patients who died in hospital. Data were missing for 4 patients who were pronounced dead shortly after arrival in the emergency department [no antemortem investigations performed].

Tables

  • Figures
    • View popup
    Table 1: Summary of 27 deaths associated with the use of paramethoxymethamphetamine (PMMA) in Alberta and British Columbia, June 2011 to April 2012
    CaseLocation and circumstances
    around presentation and death
    Drug(s) believed to have been consumedPostmortem findings
     1Took drugs at home; became unwell, friend called 911; died in EREcstasyPulmonary edema, CAD
     2Took ecstasy alone; found 9 hours later; died in ER after unsuccessful resuscitationEcstasyRapid rigor mortis
     3Took pills alone, felt unwell and self-presented to ER; died in ICUEcstasyCerebral edema, pulmonary edema
     4Took ecstasy with friends; became unresponsive; transported to ER in private vehicle; died in ICUEcstasyCerebral edema, ascites, pleural effusion
     5At house party after taking drugs; became unresponsive; transported to hospital via EMS; died in ICUEcstasyRhabdomyolysis
     6Found unresponsive at house party; transported to hospital via EMS; had cardiac arrest, died in ICUEcstasy, alcoholNo autopsy
     7At house party; found unresponsive after last seen 1.5 hours earlier; transported to hospital via EMS, had cardiac arrest; died in ICUEcstasyNo autopsy
     8Found dead in bed at homeUnknownTrivial soft-tissue abrasions
     9At house party with friends; became unwell; cardiac arrest after intubation with EMS; died in ICU8 tabs of ecstasyLung congestion, patchy pneumonia
    10Watching live performance; became unwell; cardiac arrest with EMS; died in ER after unsuccessful resuscitation1–2 g of MDMA, cocaineCardiomegaly, spleen congestion
    11At nightclub; became unwell; transported to ER in private vehicle; died in ICU6 tablets of MDMA, hallucinogenic mushrooms, LSDNo autopsy
    12Found dead at homeUnknownPulmonary congestion, cerebral edema, mottled myocardium, cardiomegaly
    13Friend noticed patient acting abnormally; transported to hospital in private vehicle after seizure; died in ER2 snorts of MDMA/ecstasy powderCongestion of heart, lungs and liver
    14Took drugs at house party; found unconscious outside at nearby property; died in ER after unsuccessful resuscitationUnknown amount of white powder believed to be ecstasyCongestion of heart, lungs, liver and spleen, cerebral edema
    15At a bar with friends; that night at home had a witnessed seizure, followed by cardiac arrest; pronounced dead upon EMS arrivalUnknownPulmonary edema, congestion of heart, liver and spleen, cerebral edema
    16Took 2 doses of ecstasy at bar; began acting strange upon return home with friends; had seizure en route to hospital with EMS, and cardiac arrest in ER; died in ER after unsuccessful resuscitation2 pills of ecstasyPulmonary edema, kidney and spleen congestion, interstitial hemorrhage in heart
    17At home with friends drinking and taking drugs; found dead the next morningCocaine, MDMA, alcoholFatty liver, unremarkable post mortem
    18At a house party; felt unwell, called 911; cardiac arrest soon after EMS arrival; died in ER after unsuccessful resuscitationUnknown white powder snortedRib and sternal fractures, pulmonary edema, advanced cirrhosis, enlarged spleen
    19Took MDMA powder the night before; felt unwell; found unresponsive the next afternoon; pronounced dead with EMS1.5 g of MDMA rolled in paper and ingestedCerebral and pulmonary edema
    20Took drugs throughout the night at home; had cardiac arrest; died in ER after unsuccessful resuscitationMDMA, cocainePulmonary congestion, cardiomegaly, nephrosclerosis
    21At party the night before with friends; found dead at home the next dayEcstasy, cocaineEdema and congestion of lungs, liver, spleen and kidneys
    22Last seen 3 days earlier; police/EMS attended; pronounced dead at the sceneUnknownPulmonary congestion
    23Partying with friends the night before; no history of drug use; found dead the next dayUnknownPulmonary edema
    24Last seen 3 days prior. Police/EMS attended, dead on scene.Cocaine, alcoholCongestion of lung, liver, spleen and kidneys
    25At house party; took multiple doses of MDMA through the night by snorting and ingestion; became confused and unresponsive; friends called 911; died in ER after unsuccessful resuscitation0.5 g of MDMAPulmonary congestion
    26At party with friends; EMS called; cardiac arrest after intubation; resuscitated in ER, died in ICU7 tabs of MDMANo autopsy
    27At concert; took drugs and alcohol; pronounced dead at home with EMSMDMA, cocaine, alcoholNo autopsy

    Note: CAD = coronary artery disease, EMS = emergency medical services, ER = emergency department, ICU = intensive care unit, LSD = lysergic acid diethylamide, MDMA = methylenedioxymethamphetamine.

      • View popup
      Table 2: Results of antemortem laboratory investigations for patients transported to hospital (n = 13/17)*
      InvestigationLevel, median (range)Normal range†
      Peak potassium, mmol/L7.0 (4.4–12.5)3.5–5.1
      Peak creatinine, mmol/L214 (146–1127)50–110
      Peak AST, U/L2944 (116–5124)7–40
      Peak creatinine kinase, U/L8200 (1952–237 960)38–215
      Lowest recorded glucose, mmol/L1.9 (0.4–17.1)3.9–6.1

      Note: AST = aspartate transaminase.
*Data missing for 4 patients; they were pronounced dead shortly after arrival to the emergency department (no antemortem investigations).
†Normal values were obtained from the Royal College of Physicians and Surgeons of Canada. (17)

        • View popup
        Table 3: Therapies provided by emergency medical services or in hospital for patients transported to hospital (n = 9/17)*
        TherapyNo. (%) of patients
        Intubation9(100)
        Paralysis6(67)
        Sedation5(56)
        Cooling
        Ice packs4(44)
        Cooled intravenous fluid2(22)
        Cyproheptadine1(11)
        Cooling blanket1(11)
        Cooling catheter1(11)

        *Data missing for 8 patients.

          • View popup
          Table 4: Results of toxicologic analysis
          CaseSpecimen typeToxin, mg/LOther findings*
          PMMAPMAMDMAMDAMAMPAMPCocaineBE
           1Postmortem blood†1.60.172.30.120.840.024NDNDLidocaine
           2Postmortem blood†NSQNSQ3.90.12NDND0.383.9PMMA vitreous 0.69 mg/L; MDMA vitreous 1.4 mg/L; cannabinoids
           3Antemortem blood†1.20.0930.990.036NDNDND0.32
           4Antemortem blood†1.60.0980.520.021NDNDNDNDLorazepam
           5Postmortem blood†1.8ND0.6NDNDNDNDNDMorphine, lidocaine, cannabinoids
           6Antemortem blood†0.110.0230.140.015NDNDNDNDMidazolam, temazepam, rocuronium metabolite, acetaminophen
           7Antemortem blood†URPURP0.32NDNDNDNDND
           8Postmortem IVC blood3.330.423.090.172.280.07NDNDDextromethorphan 0.66 mg/L, acetaminophen 18.2 mg/L, ketamine, oxycodone
           9Antemortem serum†0.940.070.09Trace0.3TraceNDND
          Postmortem IVC blood0.14TraceTraceTrace0.11TraceNDND
          10Antemortem blood†2.280.10.31Trace0.75TraceND0.19
          Postmortem femoral blood4.410.250.6Trace1.47TraceTrace0.26
          11Antemortem blood†0.440.08TraceTrace0.18TraceTNPTNPDrug screen not performed (limited specimen)
          12Postmortem IVC blood3.740.111.64TraceNDNDNDNDEthanol 30 mg/100 mL
          13Antemortem blood†1.250.070.11Trace0.35TraceND0.11
          Postmortem IVC blood2.670.180.26Trace0.8TraceND0.17
          14Postmortem IVC blood2.70.120.29Trace0.86TraceNDND
          Postmortem central blood4.350.180.43Trace1.280.05NDND
          15Postmortem IVC blood2.970.080.32TraceNDND0.040.3Acetaminophen 10.6 mg/L, codeine 0.07 mg/L, atropine
          16Postmortem IVC blood1.670.150.27Trace0.63TraceTrace0.2Oxycodone (trace), delta-9- tetrahydrocannabinol 2.3 ng/mL, carboxy- tetrahydrocannabinol 11.8 ng/mL
          17Postmortem IVC blood4.880.221.120.041.780.060.080.84Levamisole, phenacetin
          18Postmortem femoral blood3.560.331.70.12TraceNDND0.67Benzylpiperazine
          19Postmortem central blood0.650.062.580.06NDNDNDNDEthanol 10 mg/100 ml.
          20Postmortem femoral blood15.70.750.65TraceNDNDNDNDDiphenhydramine
          21Postmortem femoral blood6.190.510.26TraceNDNDNDNDDextromethorphan
          22Postmortem iliac blood5.361.080.60.051.450.1Trace0.11Oxycodone 2.01 mg/L, ibuprofen
          23Postmortem femoral blood6.340.230.34TraceNDNDTrace1.16Benzylpiperazine 1.65 mg/L, TFMPP 0.47 mg/L, ketamine, levamisole
          24Postmortem femoral blood3.580.230.16TraceNDNDNDNDBenzylpiperazine 1.00 mg/L, TFMPP 0.15 mg/L
          25Antemortem blood†1.60.10.14Trace0.47TraceTrace1.09Ketamine 0.71 mg/L, midazolam
          26Antemortem blood†3.270.090.16TraceNDNDTrace0.53
          Postmortem iliac blood3.830.140.19TraceNDNDTrace0.55
          27Postmortem iliac blood2.170.081TraceNDND0.050.46Ethanol 10 mg/100 mL, naproxen

          Note: AMP = amphetamine, BE = benzoylecgonine (metabolite of cocaine), IVC = inferior vena cava, MDA = methylenedioxyamphetamine, MAMP = methamphetamine, ND = none detected (below level of detection), NSQ = not sufficient quantities, PMA = paramethoxyamphetamine, TFMPP = trifluoromethylphenylpiperazine , trace = detected but below level of quantitation, TNP = test not performed, URP = urine positive for drug but insufficient antemortem blood available to permit quantitation.
*Unless otherwise specified, drugs in this column were not quantitated.
†Not otherwise specified.

            • View popup
            Table 5: Antemortem and postmortem concentrations of PMMA in whole blood (n = 25/27)*
            Blood sampleConcentration, mg/L, median (range)
            Antemortem blood1.43 (0.11–3.27)
            Postmortem IVC and central blood2.84 (0.14–4.88)
            Postmortem femoral and iliac blood4.41 (2.17–15.7)

            Note: IVC = inferior vena cava, PMMA = paramethoxymethamphetamine.
*Insufficient blood sample for quantitation in case 2; antemortem urine test positive in case 7, but no postmortem blood test performed.

            PreviousNext
            Back to top

            In this issue

            CMAJ Open: 3 (1)
            Vol. 3, Issue 1
            13 Jan 2015
            • Table of Contents
            • Index by author

            Article tools

            Respond to this article
            Print
            Download PDF
            Article Alerts
            To sign up for email alerts or to access your current email alerts, enter your email address below:
            Email Article

            Thank you for your interest in spreading the word on CMAJ Open.

            NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

            Enter multiple addresses on separate lines or separate them with commas.
            Deaths from exposure to paramethoxymethamphetamine in Alberta and British Columbia, Canada: a case series
            (Your Name) has sent you a message from CMAJ Open
            (Your Name) thought you would like to see the CMAJ Open web site.
            CAPTCHA
            This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
            Citation Tools
            Deaths from exposure to paramethoxymethamphetamine in Alberta and British Columbia, Canada: a case series
            Jennifer J.E. Nicol, Mark C. Yarema, Graham R. Jones, Walter Martz, Roy A. Purssell, Judy C. MacDonald, Ian Wishart, Monica Durigon, Despina Tzemis, Jane A. Buxton
            Jan 2015, 3 (1) E83-E90; DOI: 10.9778/cmajo.20140070

            Citation Manager Formats

            • BibTeX
            • Bookends
            • EasyBib
            • EndNote (tagged)
            • EndNote 8 (xml)
            • Medlars
            • Mendeley
            • Papers
            • RefWorks Tagged
            • Ref Manager
            • RIS
            • Zotero
            Share
            Deaths from exposure to paramethoxymethamphetamine in Alberta and British Columbia, Canada: a case series
            Jennifer J.E. Nicol, Mark C. Yarema, Graham R. Jones, Walter Martz, Roy A. Purssell, Judy C. MacDonald, Ian Wishart, Monica Durigon, Despina Tzemis, Jane A. Buxton
            Jan 2015, 3 (1) E83-E90; DOI: 10.9778/cmajo.20140070
            Twitter logo Facebook logo Mendeley logo
            • Tweet Widget
            • Facebook Like

            Related Articles

            • PubMed
            • Google Scholar

            Cited By...

            • Awareness, predictors and outcomes of drug alerts among people who access harm reduction services in British Columbia, Canada: findings from a 2021 cross-sectional survey
            • Google Scholar

            Similar Articles

            Keywords

            • Presented at the North American Congress of Clinical Toxicology
            • Sept. 1
            • 2013
            • Atlanta
            • GA

            Content

            • Current issue
            • Past issues
            • Collections

            About

            • General Information
            • Staff
            • Editorial Board
            • Advisory Panel
            • Contact Us
            • Reprints
            • Copyright and Permissions
            CMAJ Group

            Copyright 2025, CMA Impact Inc. or its licensors. All rights reserved. ISSN 2291-0026

            All editorial matter in CMAJ OPEN represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

            To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected].

            CMA Civility, Accessibility, Privacy

             

             

            Powered by HighWire